JMP Securities raised the firm’s price target on Aquestive Therapeutics to $10 from $8 and keeps an Outperform rating on the shares. Aquestive on Thursday announced positive top-line results from its pivotal pharmacokinetic trial for Anaphylm, meeting all primary and secondary endpoints, and JMP remains confident that the company has clear alignment with the FDA on the path to approval, including the design of an allergen-induced study, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AQST:
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
- Aquestive Therapeutics price target raised to $7 from $6 at H.C. Wainwright
- Aquestive Therapeutics price target raised to $8 from $3 at Lake Street
- Aquestive Therapeutics Updates Investors with Presentation and Financials
- Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
